Already offering the only non-invasive treatment for SMA in liquid form, Roche’s Evrysdi now comes as a tablet.

Simplified storage and administration of new tablet formulation may provide greater freedom and independence for people with SMA ; Evrysdi offers the same efficacy and safety demo ...

Bayer’s Vividion Therapeutics has secured the global rights from its partner Roche to the only Werner helicase (WRN) inhibitor to have made it into the clinic.

The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to ...

While the approval is a historic event for the BiTE drug class in solid tumours, the market share opportunity is restricted ...

The shift toward universal screening for diseases like hepatitis C, hepatitis B, and HIV removes part of the burden of ...

Regeneron Pharmaceuticals has announced that it will be gaining rights to Hansoh Pharmaceuticals’ investigational dual ...

Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced it has secured exclusive ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Newseria nie ponosi odpowiedzialności za treści oraz inne materiały (np. infografiki, zdjęcia) przekazywane w „Biurze ...

Importance of pharmacovigilance and medication safety in evolving pharma landscape: Dr. Supriya Shidhaye Wednesday, June 4, 2025, 08:00 Hrs [IST] The pharmaceutical industry stand ...

US President Donald Trump on May 23 threatened to impose a 50 percent tariff on all imports from the European Union.